Torrent Pharmaceuticals declines on getting 1 observation from USFDA for Gujarat facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Torrent Pharmaceuticals is currently trading at Rs. 1516.00, down by 14.50 points or 0.95% from its previous closing of Rs. 1530.50 on the BSE.
The scrip opened at Rs. 1532.25 and has touched a high and low of Rs. 1532.30 and Rs. 1501.25 respectively. So far 3613 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1722.70 on 09-Nov-2022 and a 52 week low of Rs. 1242.50 on 12-May-2022.
Last one week high and low of the scrip stood at Rs. 1563.00 and Rs. 1491.05 respectively. The current market cap of the company is Rs. 51565.55 crore.
The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 20.96% and 7.80% respectively.
The United States Food and Drug Administration (USFDA) has concluded Pre-Approval Inspection (PAI) at Torrent Pharmaceuticals’ Oral-Oncology manufacturing facility at Bileshwarpura, Gujarat from March 13, 2023 to March 17, 2023. At the end of the inspection, the company has been issued a ‘Form 483’ with 1 observation, which is procedural in nature.
Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
